ADARx Pharmaceuticals (ADRX) Stock Price, News & Analysis

Company Overview

ADARx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-based medicines for immune-mediated and other serious diseases. The company is headquartered in San Diego, California, and uses proprietary technologies designed to modulate disease-related proteins at the RNA level.

ADARx’s pipeline includes investigational therapies intended to address conditions involving the complement system, coagulation pathways and other biologic mechanisms. Its programs are designed to provide targeted, durable treatment through approaches such as RNA interference and related forms of RNA-based therapeutic intervention.

Founded in 2018, ADARx has advanced its drug candidates through preclinical and clinical development and has pursued regulatory and clinical activities in the United States and other international markets. As a development-stage biotechnology company, its products remain investigational and are subject to clinical testing and regulatory review.

Key Stats

• Today's Range: $17.57 to $18.82
• 50-Day Range: N/A
• 52-Week Range: $16.64 to $23.21
• Volume: 220,985 shs
• Average Volume: 846,066 shs
• Market Capitalization: $1.89 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ADRX
• CIK: 1802369
• Web: www.adarx.com
• Phone: (858) 283-9472
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 106,800,000
• Free Float: N/A
• Market Cap: $1.89 billion
• Optionable: N/A
• Beta: N/A